Targeted liposomal delivery of cGMP analogues

US10322087B2 · kind B2 · utility

Assignee

• MIRECA MEDICINES GMBH · DE

Inventors

• Per EKSTRÖM · Lund, SE
• Francois PAQUET-DURAND · Tübingen, DE
• Pieter Jaap Gaillard · Leiden, NL
• Valeria Marigo · Modena, IT
• Hans-Gottfried Genieser · Lemwerder, DE
• Andreas Rentsch · Bremen, DE
• Dragana Trifunovic · Tübingen, DE
• Ayse Sahaboglu Tekgoz · Tübingen, DE

Key dates

• Filing date: Mar 16, 2016
• Grant date: Jun 18, 2019
• Expiry date: Mar 16, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S977/907
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′, 5′-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.